Celebrating Israel

Share on:

Yom Ha’atzmaut – Israel Independence Day – begins at sundown on Tuesday, April 28th, 2020. 

On on this day, we are filled with gratitude and pride for all that has been achieved in Israel’s 72 years of statehood. For generations,Technion engineers, architects and scientists have played a pivotal role building the infrastructure and high-tech industries of modern Israel – establishing one of the most creative and innovative countries in the world.

Today, Technion and Israel are at the forefront of the worldwide fight against COVID-19 and Israeli innovation is sure to be a critical factor in beating the pandemic.

With your support, Technion will continue to strengthen Israel for generations to come.  HAPPY BIRTHDAY ISRAEL!

18 Incredible Inventions

Discover and share how much value Israel provides the world through groundbreaking achievements with this unique online exhibition “18 Ways Israel is Changing the World”. Featuring Technion DNA; Nanose, Rewalk, Insightec. 




Collaboration is the Best Weapon

Israel is united in the fight against COVID-19. The Government Companies Authority launched an initiative to form a connection between hospitals, defense companies, and the Ministry of Health to develop new medical technologies to combat Coronavirus.

Discover how the Technion is involved in this powerful collaboration.



Life Saving Innovation

Ambo-Vent may offer an answer to the global shortage of ventilators in the battle against COVID-19. An Israeli group made up of Air Force electronics experts, robotics specialists, and medical professionals has come up with an innovative hack that could help hospitals around the world produce ventilators quickly and at low cost.



A New Era

Chemi Peres, son of Simon Peres, shares the powerful story of Israeli innovation and what is next for the Start-Up Nation. He stresses the need for global collaboration to solve world wide crises like the corona virus pandemic and climate change threats. “We are transitioning…to a new era where the source of power, the source of greatness, is coming from brainpower, from the mind.”



Israel at Forefront of Corona Virus Vaccine Research

Israeli scientists are at the cutting edge of Coronavirus vaccine research. As the World Health Organisation announces 70 trials for a vaccine are ongoing, teams at Technion in Haifa and MIGAL in Kiryat Shmona are among those at the forefront of testing.




The Technion has been there for Israel since the beginning, and Technion advances in science and technology continue to strengthen the State of Israel and the world. We are stronger together and together we can build a brighter future for us all.  Support Technion now.






A Cheap, Fast Coronavirus Home Test

Share on:
Dr. Naama Geva-Zatorsky

Led by Professor Naama Geva-Zatorsky, a Technion research team is developing a home kit that would enable people to be quickly and inexpensively tested for the coronavirus, without the need for elaborate lab equipment.

The kit has successfully identified the virus in saliva samples, which unlike swab tests, do not require expertise. The researchers say the kit is 99% accurate.


Le génie médical au Technion

Share on:
Dr. David Bensoussan

Nous sommes fier de partager cette article, écrit par David Bensoussan, un ancien de Technion, qui examine les avances réalisé par les graduées et chercheurs du Technion. Présentée cette semaine dans Times of Israel.

Examine les nombreuses avances réalisées par les techniciens et les anciens.

We are proud to share this article written by Technion alumnus, David Bensoussan, which explores the medical advances achieved by Technion researchers and alumni.  Featured this week in the Times of Israel.  


New Hope for Coronavirus Patients with Acute Respiratory Distress Syndrome

Share on:
Reconstructed lung model developed at the Technion

Prof. Josué Sznitman and his team from the Technion have developed an innovative technology that could dramatically improve the efficacy of existing drugs for treating Acute Respiratory Distress Syndrome (ARDS), which is recognized as the leading cause of mortality in COVID-19 patients. Due to the global crisis, the development of Sznitman’s technology is being fast-tracked.

Sznitman and his team are in a race to launch clinical trials within a few months and evaluate the new technology for treating severe Coronavirus patients suffering from ARDS. To date, there is no existing therapy to treat ARDS patients. These patients undergo assisted ventilation and oxygenation, oftentimes under intubation, in intensive care units (ICUs).

One of the hallmarks of ARDS is damage to pulmonary surfactant (the liquid that coats the surface of alveoli in the lungs). Surfactant has many roles, but perhaps most importantly it reduces the forces required for breathing. While research is ongoing in understanding the SARS-COV-2 virus, it was recently shown that the virus kills the epithelial cells that secrete surfactant inside alveoli, after binding to a receptor (called ACE2) on the cell’s surface. Sznitman’s team hypothesizes that surfactant depletion may be particularly severe in COVID-19 related ARDS.

Surfactant Replacement Therapy (SRT) exists and is an established and life-saving clinical procedure in treating a similar type of ARDS that affects preterm newborn children, whose immature lungs lack pulmonary surfactant. In neonates, SRT is based on endotracheal administration of liquid surfactant (i.e. injecting external surfactant into the neonate’s lungs). As a result of differences in lung size, this delivery method has been highly ineffective in adults. Liquid instillations are strongly affected by gravity and thus quickly drain into pools, drowning some lung regions while leaving others entirely untreated.

The patent-pending technology, invented by Dr. Yan Ostrovski and Prof. Sznitman, and known as Liquid Foam Therapy (LIFT), is intended to dramatically improve the distribution of surfactant across the lungs. More generally, LIFT is a radical new method for pulmonary drug delivery with the potential of delivering therapeutics homogeneously into the lungs and, importantly in large doses. This is accomplished by loading the drug within the foam, or alternatively foaming the drug directly when possible. In both cases, and unlike liquids, the foam defies gravity and prevents the formation of pools.

In their findings (to be soon submitted for scientific publication and subject to rigorous peer-review), the team thoroughly examined in a preclinical in vivo study, the safety and efficacy of employing LIFT with foamed surfactant in a severe ARDS model induced in rats. There, the rats recovered a healthy state within 15-30 minutes, with no adverse events. As rat lungs are too small to demonstrate improved distribution that is critically sought in adult lungs, the team used ex vivo experiments in adult-sized porcine lungs to show how LIFT spreads homogenously compared with liquid administration.

Following these encouraging results, the team is now in a race to construct a fully functional delivery device and move to a preclinical in vivo study in severe ARDS models in pigs. If successful, the researchers will pursue the first clinical trials of the therapy, in an effort to critically accelerate the development of a treatment for the most severe COVID-19 patients with ARDS. The LIFT technology will be licensed to the newly founded start-up company, Neshima Medical, led by Dr. Ostrovski and supported by the Technion’s Business Development Unit T3.


Protecting Medical Workers from COVID-19

Share on:

New High-Tech Sticker Improves the Effectiveness of Surgical Masks and Protects Medical Staff against COVID-19

Prof. Eyal Zussman of the Faculty of Mechanical Engineering at Technion and the COVID-19 National Emergency Team of the Defense Ministry’s Directorate of Defense R&D (DDR&D) have developed a unique sticker that can be affixed to surgical masks and renders them more effective. The sticker was developed in conjunction with the Galilee Medical Center in Nahariya. The new device will reduce the instances of infection and provide improved protection for the medical staff.

Prof. Zussman is the head of the Nano-Engineering Lab in the Faculty of Mechanical Engineering. Together with the lab team, he developed a unique sticker that is affixed to standard surgical masks and improves their effectiveness. The sticker, named ‘Maya,’ is manufactured using a 3D printer and consists of nanometric fibers coated with antiseptics – which improves the trapping of nanometric particles and efficiently neutralizes viruses from droplets that might reach the mask.

The sticker was developed in partnership with scientists from the Chemical and Biological Section of the DDR&D, led by Dr. Dan Greenstein in partnership with Prof. Samer Srouji, Director of Oral Surgery at the Galilee Medical Center in Nahariya.

The Ministry of Health has granted the ‘Maya’ sticker a preliminary approval and in upcoming days a pilot project will begin at the Galilee Medical Center to assess the adaptability of the medical staff to the sticker. Dr. Masad Barhoum, General Director of the Galilee Medical Center, thanked the Ministry of Defense and Technion for the fruitful collaboration and expressed his hope that the new sticker will reduce the incidence of COVID-19 infection among the medical staff. “This is an available and fast solution based on sophisticated technology. We hope that the pilot project will succeed and that this unique innovation will be introduced to many other hospitals around the country,” said Srouji.

The COVID-19 National Emergency Team continues to search for and develop advanced technologies that will help fight the spread of the virus. The Team is adapting defense technologies to civil applications. They are working around the clock in order to swiftly bring tested solutions to answer the critical needs of the hospitals.